Using FDA Product Specific Guidances (PSGs) as a Trigger for Generic Drug Development
Drug Patent Watch
DECEMBER 11, 2024
These guidances serve as a roadmap for companies looking to develop generic versions of brand-name drugs, offering invaluable insights into the FDA’s expectations for demonstrating bioequivalence and ensuring product quality. They provide recommendations on the design of in vitro and in vivo studies.
65 
Let's personalize your content